Kornimate/medical-research-clean huggingface dataset:
imunor® preparation in the prevention of covid-19

Conditions: Covid19

Summary: the aim of the study is to achieve prevention of covid-19 disease in healthcare professionals with the administration of the imunor® preparation, and decreasing the symptoms should the disease appear.

this prospective study is designed to collect data for evaluation of the preventive and therapeutic effect of the imunor® preparation, which is commonly used to treat patients with laboratory or clinical manifestations of immunity disorders. administration of immunomodulation treatment will be based upon a willing informed consent with the administration of the drug and based upon random selection. the study subjects will receive imunor® preventively; the anticipated preventive effect when using one packing (4 vials) is 6 weeks, and 12 weeks when using two packings. should any signs of acute illness appear (increased body temperature, cough, loss of smell and taste, etc.), a treatment dose of imunor®, i.e. 1 vial/day (total of 4 vials) will be administered immediately. monitoring of individual patients will take 6 weeks (1 packing) or 12 weeks (2 packings) from the beginning of imunor® administration. the clinical condition of study subjects will be monitored on a daily basis. at the same time, the possible onset of symptoms will be recorded. the obtained data will be compared with a control group consisting of patients followed by the department of preventive medicine, university hospital ostrava.

Eligibility criteria:
inclusion criteria: * study subjects 18-60 years old * ability to cooperate upon the study and to give informed consent exclusion criteria: * use of any other immunomodulation treatment one month prior to enrolment and in the course of the study * acute disease of the cardiovascular, urogenital, respiratory or nervous system

Keywords: covid19 prevention pork dialyzed leukocyte extract immunomodulation
tumor microenvironment in gastric cancer patients treated with combined immunotherapy and chemotherapy

Conditions: Gastric Cancer; Tumor Microenvironment; Immunotherapy; Chemotherapy

Summary: the goal of this study is to analyze the tumor microenvironment (tme) in gastric cancer patients treated with combined immunotherapy and chemotherapy. the main questions it aims to answer are: * provide profiles of tme between pre-treatment and post-treatment to gain insights into the mechanisms of immunotherapy combined with chemotherapy in advanced gastric cancer * investigate the crucial factors affecting treatment efficacy by comparing gastric cancer patients with varying treatment responses


Eligibility criteria:
inclusion criteria: * non-bedridden, aged 18 to 70 years old; * eastern cooperative oncology group (ecog) score is 0 to 1; * histologically confirmed gastric adenocarcinoma with evaluable lesions based on recist 1.1; * advanced gastric cancer; * ready for receiving s-1 plus oxaliplatin chemotherapy and either nivolumab or sintilimab exclusion criteria: * history of other malignant diseases in the last 5 years; * prior chemotherapy, radiotherapy or immunotherapy; * not receiving s-1 plus oxaliplatin chemotherapy and either nivolumab or sintilimab.
iron substitution after total knee arthroplasty

Conditions: Haemodynamic Rebound

Summary: hemoboost is a registered natural product containing specially processed haemolysed haemoglobin and iron dextran. it is marketed for human use on the basis of many years' use and documented effect in veterinary medicine. iron dextran was introduced for use in human medicine in 1954. krauterblut is a registered natural product made from a number of herbs where the active substance is ferrous gluconate. both drugs have been available for a number of years and have become increasingly popular among patients and healthcare staff due to a reduction in adverse effects. the objective of this study is to determine the effect and adverse effects of the natural products hemoboost and kräuterblut compared with the usually administered ferrous sulphate in knee arthroplasty.

hip and knee arthroplasties are performed with increasing frequency in the western world, and in denmark approximately 12,000 operations are performed annually (2/1000/year). the perioperative and postoperative blood loss generally constitutes ½ -1½ litres which is frequently associated with symptom-producing anaemia which obstructs mobilisation and increases the risk of complications. postoperative iron supplementation for a period of up to 12 weeks is therefore a frequently adopted practice. however, there is no consensus or evidence that support postoperative iron supplementation and the effects of iron deficiency are unclear. it is well-known that iron supplementation causes gastrointestinal adverse effects in up to 25% of cases.

Eligibility criteria:
inclusion criteria: * age \> 18 years * asa group i-ii exclusion criteria: * malignant disorder * chronic renal insufficiency * urinary tract infection * haemorrhagic diathesis * haemoglobin \< 7 mmol/l * dementia or mental disorder incompatible with survey participation

Keywords: iron supplementation iron deficiency hip arthroplasty knee arthroplasty
physical function of older citizens during municipality-based rehabilitation

Conditions: Aging; Rehabilitation; Frailty; Sarcopenia; Fractures, Bone; Musculoskeletal Pain; Musculoskeletal Diseases; Musculoskeletal Injury; Muscle Weakness; Weakness, Muscle

Summary: when choosing outcomes to assess rehabilitation's effect or progress, it is essential to consider the constructs being measured and their value to the patient and the psychometric properties. choosing an outcome that reflects all aspects of international classification levels of functioning, disability and health (icf) is challenging, especially in heterogeneous groups. however, it is important to know the psychometric properties as this gives important knowledge on how to interpret results and, consequently, how this can inform the patient's care. the short musculoskeletal function assessment (smfa) questionnaire can reflect differences in patients' functional status with a broad range of disorders, like for elderly citizens undergoing municipality-based rehabilitation. nevertheless, since there is no golden standard to measure rehabilitation outcomes, construct validity needs to be established to investigate how scores of smfa can be related to measures on all levels of icf. therefore, this study has three main objectives: 1. to investigate how scores of the smfa questionnaire are related to measures on different icf levels 2. to describe the characteristics of older citizens starting municipality-based rehabilitation on all icf levels 3. to investigate predictor variables of upper- and lower extremity strength

the present study is a sub-study to the randomized controlled trial (nct04091308). the present study aims to include 115 participants who will undergo measures specified in the "outcome" section. the principal investigator of the study will conduct the testing.

Eligibility criteria:
inclusion criteria: all citizens that are referred to the health/rehabilitation center aged ≥ 65 years from slagelse municipality will be invited to a screening interview with a physiotherapist after which the participant will be asked to join the study if not subject to one of the following exclusion criteria's: exclusion criteria: * inability to speak or read danish, * active cancer, * upper or lower limb amputations, * hypertension \>180/110, * referred to rehabilitation primarily due to gynecological or neurological conditions (apoplexies) or surgeries where movement restrictions prohibit participating in most of the tests, * discouragement from a general practitioner.

Keywords: smfa sf36 icf older rehabilitation
clinical presentation and renal outcome of patients with tuberous sclerosis complex and/or renal angiomyolipoma in the great west region of france

Conditions: Tuberous Sclerosis Complex

Summary: this study aims to investigate the factors (clinical, care-related and genetic) affecting renal outcome in patients with tsc (tuberous sclerosis complex)


Eligibility criteria:
inclusion criteria of study participants * patient presenting with an isolated angiomyolipoma or * patient presenting with tuberous sclerosis complex combined with an angiomyolipoma or * patient presenting with tuberous sclerosis complex * patient not objecting to the study exclusion criteria of study participants ■patient objecting to the study
the utility of platelet rich plasma in hair loss

Conditions: Androgenetic Alopecia

Summary: platelet rich plasma (prp) is an autologous preparation of human plasma with high concentration of platelets. platelets release numerous growth factors, which stimulate cell proliferation and differentiation. the purpose of this research is to investigate the potential of prp injection for treatment of hair loss. clinical outcomes will be assessed by noninvasive techniques including dermoscopy, multiphoton microscopy, optical coherence tomography, optical doppler tomography and multispectral imaging.


Eligibility criteria:
inclusion criteria: * over 18 years of age * ability to understand and carry out instructions * diagnosed with alopecia exclusion criteria: * inability to understand and.or carry out instructions * pregnant women * use of any topical medication (such as minoxidil or any other solution for hair growth), oral medication (finasteride, dutasteride, or antiandrogens), laser therapy, or chemotherapy, within the preceding 4 weeks. * personal medical history of bleeding disorders * personal medical history of platelet dysfunction syndrome * anti-coagulation therapy or nonsteroidal anti-inflammatory drugs in the last 1 week.
wilson's disease treated with d-penicillamine: characterization of skin damage secondary to treatment by measuring skin elasticity

Conditions: Wilson Disease; D-Penicillamine

Summary: wilson's disease is a genetic disorder, resulting from an anomaly present on the atp7b gene located on chromosome 13, causing a progressive accumulation of copper in various organs such as the liver, nervous system and cornea, leading to various hepatic and neurological disorders and a systemic evolution. currently, the first-line treatment for this disease is d-penicillamine, which acts by chelation and promotes copper excretion through the urine. unfortunately, this treatment also has significant side-effects, particularly on the skin. however, the pathogenesis of elastopathy in patients with wilson's disease has yet to be fully characterized, and needs to be better understood in order to adapt the therapeutic strategy. a silicon mold will be made on wilson's disease patients, enabling the skin micro-relief to be shaped, and analyzed by confocal laser in comparison with the skin of healthy volunteers.


Eligibility criteria:
inclusion criteria: diseased patients : * patient over 12 years old * patient with wilson's disease confirmed by genetic analysis * patient followed up in the wilson's disease reference center for his care * patient treated with d-penicillamine * patient with no other known elastic tissue pathology healthy volunteers : * patient over 12 years old * patient followed up in the dermatology department of st etienne university hospital * patient matched on sex and age with a patient from the "wilson's disease" group * patient with no elastic tissue pathology all patients : * patient affiliated to a national social security * patient with written informed consent exclusion criteria: all patients: * patient not taking a treatment (at investigator's discretion) that may modify skin elasticity * patient with pathological lesion(s) on forearm or cheek * patient with a potentially active/rejuvenative forearm or cheek treatment * patient having applied cream and/or make-up to the areas to be molded (forearm and cheek) * patient under guardianship * patient unable to follow study procedures * pregnant or breast-feeding women

Keywords: cutaneous elastopathy
real world testing of a brain-computer interface

Conditions: Amyotrophic Lateral Sclerosis; Brain Stem Stroke; Cerebral Palsy; Traumatic Brain Injury; Speech Disorders

Summary: the goal of this project is to test a new aac-bci device comparing gel and dry electrode headgear used for communication while providing clinical care. innovative resources will be employed to support the standard of care without considering limitations based on service billing codes. clinical services will include aac assessment, aac-bci device and treatment to individuals with minimal movement due to amyotrophic lateral sclerosis (als), brain stem strokes, severe cerebral palsy, traumatic brain injury (tbi) and their family support person. this is a descriptive study designed to measure and monitor the communication performance of individuals using the aac-bci, any other aac strategies, their user satisfaction and perceptions of communication effectiveness, and the satisfaction of the family support persons.

this clinical trial follows a descriptive study design collecting data to measure and monitor variables related to the standard of care in providing speech language pathology augmentative and alternative communication clinical (aac) assessment and treatment. the study tracks participants through the aac, speech generating device trial and aac-bci trial processes. in addition this study measures and monitors the communication performance of individuals using the aac-bci and any other aac strategies for treatment in the home. data on communication performance, user satisfaction, and perceptions of communication effectiveness are gathered over monthly visits along with the satisfaction and perceptions of communication effectiveness by the family support persons.

Eligibility criteria:
inclusion criteria: * natural speech does not meet daily communication needs requiring using a speech generating device * has a diagnosis resulting in minimal movement interfering with direct selection to a keyboard or aac display * age 14 and above * able to read a standard computer screen * able to follow instructions * english as their native language exclusion criteria: * history of photosensitive epilepsy * open sores on the scalp * history of uncorrectable hearing loss * unavailable to participate during the times scheduled for the study
comparison of two bending angles for nasotracheal intubation with a malleable vedio stylet

Conditions: Intubation;Difficult

Summary: video intubating stylet can be safely and effectively used for nasotracheal intubation, but the optimal bending angle is still unknown. in this study, the optimal bending angle will be determined by comparing the intubation time and success rate of nasotracheal intubation with video intubating stylet at two different bending angles.

intubation will be accomplished at 70 bending angle and 90 degrees bending angle in each group. intubation time, success rate, additional manoeuvres and epistaxis will be recorded and compared.

Eligibility criteria:
inclusion criteria: * patients require nasotracheal intubation exclusion criteria: * fixed, or limited, neck movement, obstructive sleep apnoea, bilateral nasal obstruction or patients with an abnormal coagulation status
quality of life in patients undergoing surgery or brachytherapy for stage ii prostate cancer

Conditions: Prostate Cancer

Summary: rationale: quality of life assessment in patients undergoing prostate cancer treatment may help determine the intermediate-term and long-term effects of surgery and brachytherapy. purpose: randomized clinical trial to study quality of life in patients undergoing radical prostatectomy or brachytherapy for stage ii prostate cancer.

objectives: * compare changes in health-related quality of life (hrqol) in patients with stage ii prostate cancer up to 2 years after treatment with radical prostatectomy or brachytherapy. * compare the effect of baseline hrqol, age, and other covariates on hrqol improvement or deterioration in these patients up to 10 years after these treatments. * compare the effect of treatment modality on hrqol improvement or deterioration in these patients up to 10 years after these treatments. * compare the effects of treatment failure on hrqol, in terms of disease progression, in these patients. outline: patients are randomized to 1 of 2 arms on acosog-z0070 (radical prostatectomy vs brachytherapy). patients in both arms complete a quality of life questionnaire at baseline, 2 and 6 months after treatment, and then at 1, 2, 4, 7, and 10 years after treatment. projected accrual: a total of 500 patients (250 per group) will be accrued for this study within 2 years.

Eligibility criteria:
disease characteristics: * histologically confirmed adenocarcinoma of the prostate within the past 120 days * stage ii disease (t1c-t2a, n0, m0) * concurrent enrollment on acosog-z0070 * not yet randomized to an intervention arm (radical prostatectomy or brachytherapy) * willing and able to complete heath-related quality of life questionnaires patient characteristics: age * 75 and under prior concurrent therapy: endocrine therapy * more than 6 months since prior hormonal therapy for prostate cancer

Keywords: stage iib prostate cancer stage iia prostate cancer adenocarcinoma of the prostate
assessing alternative approaches for blood pressure control: a3bc trial

Conditions: Hypertension

Summary: an estimated 76 million adults in the united states over the age of 20 have hypertension (htn); which translates into 1 out of 3 adults. globally the prevalence of htn is over 25% for adults, and accounts for approximately 13.5% of all deaths. given the aging of the population together with increases in obesity and sedentary behavior, it is not surprising that htn is projected to increase significantly over the next several decades; with over 1.5 billion adults having htn by the year 2025. thus the public health implications to preventing and/or reducing elevations in blood pressure are substantial. this study compares the efficacy of two different non-pharmacologic interventions (device guided breathing and isometric hand grip exercises) used alone and in combination for lowering blood pressure. this pilot study will include 30 adults with stage 1 hypertension. the primary outcome is the change in blood pressure from baseline to 8 weeks. secondary outcomes include change in blood pressure from 8 weeks to 16 weeks and acceptability of the interventions by participants. the knowledge gained from this study can provide information on non-pharmacologic methods that may be useful in decreasing blood pressure. such knowledge may be especially useful for patients for whom access to medications and health care is limited and among patients unwilling to take or intolerant to pharmacologic therapies.


Eligibility criteria:
inclusion criteria: * are at least 21 years old, and * have stage 1 high blood pressure. (defined as a systolic blood pressure between 140 mm hg and 159 mm hg (the top blood pressure number) and/or a diastolic blood pressure between 90 mm hg and 99 mm hg (the bottom blood pressure number) in the prior 6 months.) exclusion criteria: * take drugs to control blood pressure. * have a history of left ventricular hypertrophy. * have a history of cardiovascular disease such as stroke, mini-strokes, heart attack, unstable angina, bypass surgery, stents, angioplasty, abnormal heart rhythms, heart failure, or peripheral artery disease. * have diabetes. * have a history of poor kidney function. * have an upper arm circumference greater than 17 inches. * are currently participating in a formal exercise or weight loss program. * plan to participate in a formal exercise or weight loss program in the next 6 months. * are pregnant or plan to become pregnant in the next 6 months.

Keywords: high blood pressure
effects of menopause hormonal therapy and selective serotonin reuptake inhibitor on cognition, sexual function and quality of life

Conditions: Menopause

Summary: cross-sectional study with postmenopausal women using hormone therapy or serotonin reuptake inhibitor to relieve climacteric symptoms or without any treatment. participants will answer three questionnaires: fsfi (the female sexual function index), menqol (menopause-specific quality of life) and meem (mini-mental state examination). the results will be compared according to treatment group.

climacteric is a period marked by the reduction of estrogen levels, which leads to the occurrence of various symptoms that can affect a woman's physical, mental, sexual health and quality of life. the use of hormonal therapy (ht), with replacement of estrogen or estrogen and progestin, is indicated to alleviate these symptoms, aiming to improve the woman's quality of life. in addition, it is possible to use other forms of treatment to alleviate these symptoms, including selective serotonin reuptake inhibitors (ssri), which play a major role in vasomotor symptoms. ssris have been used with moderate success in women who have contraindications to the use of ht or do not wish to use it. objective: this study aims to analyze and compare the effects of ht and ssris in the treatment of climacteric symptoms in relation to cognitive and sexual function and quality of life in climacteric women. methodology: this is a cross-sectional study to be carried out with menopausal women treated at the centro de atenção integral à saúde da mulher (caism) in the city of são bernardo do campo/sp/brazil. participants who sign the informed consent form will answer 3 questionnaires: fsfi (female sexual function index), whoqol-bref (world health organization quality of life instrument bref) and meem (mini-mental state examination). the results will be compared according to treatment group.

Eligibility criteria:
inclusion criteria: * postmenopausal women aged between 45 and 65 years who are literate; * patients with at least 6 months of follow-up at the institution and who consented to participate in the research. exclusion criteria: * women with psychiatric illness; * being on medication with action on the central nervous system due to psychiatric indication; * cognitive impairment that makes it impossible to understand the issues; * illiteracy; * absence of at least one sexual activity in the last 4 weeks.

Keywords: menopause hormone replacement therapy selective serotonin reuptake inhibitors sexual function quality of life cognition